Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:58:26.744Z.
Calculation as of: 2026-10-06T20:58:26.744Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9e5af3e3eb74887b0741ac42ed15d75d820cdffcd327c1f2ecbbd665592eb47e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Relmada Therapeutics, Inc.
Market Cap
$344.04M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$349.70M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.88M
EV/EBITDA Ratio
N/A
TTM Avg
37.95x
3Y Avg
29.61x
5Y Avg
22.14x
Market Cap
$355.36M
EV/EBITDA Ratio
6.50x
TTM Avg
7.04x
3Y Avg
7.63x
5Y Avg
8.90x
Market Cap
$355.43M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | $344.04M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $353.00M | 5.38x | 4.73x | 7.57x | 7.31x |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | N/A | 37.95x | 29.61x | 22.14x |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 6.50x | 7.04x | 7.63x | 8.90x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
